Bovine α-lactalbumin (α-La) contains numerous dipeptidyl peptidase IV (DPP-IV) inhibitory peptides sequences within its primary structure. In silico analysis indicated that the targeted hydrolysis of α-La with elastase should release DPP-IV inhibitory peptide sequences. An α-La isolate was hydrolysed with elastase under different conditions using an experimental design approach incorporating 3 factors (temperature, pH and enzyme to substrate ratio (E:S) ratio) at 2 levels. The hydrolyzate generated at pH 8.5, 50C, E:S 2.0% (w/w) (H9) displayed the lowest half maximal DPP-IV inhibitory concentration (IC50 = 1.20 ± 0.12 mg mL -1
Introduction
Dipeptidyl peptidase IV (DPP-IV) is an ubiquitous enzyme which is responsible for the cleavage and inactivation of the incretin hormones, glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) 1 . In the context of type 2 diabetes management, DPP-IV inhibition may be used as a means to improve the regulation of serum glucose in humans. Various DPP-IV inhibitory drugs (gliptins), have been developed to maintain the insulinotropic activity of the incretins in the post-prandial phase 2 .
Dietary components, including food protein-derived peptides, have been shown to play a role in the inhibition of DPP-IV in vitro and in certain instances in vivo, for reviews, see: 3, 4, 5 . In silico studies have shown that selected DPP-IV inhibitory peptide sequences may be found within a wide range of dietary proteins 6, 7 . To date, milk proteins appear to be the most frequently studied substrate for the generation of DPP-IV inhibitory peptides. Depending on the enzymatic strategy employed, different milk proteins may appear to be more suitable substrates for the production of DPP-IV inhibitory peptides. For instance, it was recently predicted by Tulipano et al. 8 using in silico digestion with gastrointestinal proteinases that -lactoglobulin (-Lg) should yield a higher number of previously identified DPP-IV inhibitory peptides than -La. This was further confirmed following in vitro digestion of -Lg and -La with gastrointestinal enzymes, yielding hydrolyzates with IC 50 values of 0.74 and 1.70 mg mL -1 , respectively 8 . Other in silico analysis of the major milk proteins indicated that -lactalbumin (-La) displayed the highest level of sequence coverage (43.9%) for previously identified DPP-IV inhibitory peptides as well as the highest DPP-IV inhibitory potency index (i.e., 17.9 10 -6 µM -1 g -1 ) 7 . It has been suggested that discrepancies between studies to determine the most adequate substrate for the generation of DPP-IV inhibitory peptides may arise from the lack of information on a wide set of DPP-IV inhibitory peptide sequences as well as their potency. For this reason, Lan et al., 9 have developed a peptide library approach incorporating 337 dipeptides which were evaluated for their in vitro DPP-IV inhibitory properties. It was hypothesized within this study that selected DPP-IV inhibitory peptide sequences within -La may be released during hydrolysis by careful selection of the enzyme activity. Therefore, the aim of this proof of concept study was to predict the most appropriate enzyme(s) for the release of selected DPP-IV inhibitory peptides from bovine -La and to subsequently validate the release of these peptides in vitro. This was achieved by (1) in silico prediction of the enzyme activity which should yield the highest number of known DPP-IV inhibitory peptides, (2) hydrolysis of -La with this enzyme activity using an experimental design (3 factors (temperature, pH and E:S ratio) studied at 2 levels) approach to optimize release of the predicted peptides and (3) confirmation of the release of the predicted peptides by liquid chromatographytandem mass spectrometric (LC-MS/MS) analysis. In addition, in vitro simulated gastrointestinal digestion (SGID) was used to study the stability of the DPP-IV inhibitory activity in selected hydrolyzates. 
Materials and methods

Reagents
In silico analysis
In silico digestion of bovine -La with pepsin, trypsin, chymotrypsin, elastase and glutamyl endopeptidase was carried out with the peptide cutter program available in Matlab (version R2014b, MathWorks, Inc, Natick, MA, USA), using the same cleavage rules as per ExPASy. Comparison of the peptide sequences predicted to be released to known DPP-IV inhibitory peptides previously identified in the literature 7, 9 was then carried out.
Extraction of -La from WPC80
-La was extracted from WPC80 following the method described by Fernández, et al.
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, with modifications. Briefly, -La was selectively precipitated by adjusting the pH of WPC80 to 3.5 with a 1 M citric acid solution. The pellet was washed 3 times and then resolubilized using a 0.1 M CaCl 2 solution at pH 7.5 in a 1:1 (w:w) ratio. The -La extract was then dialyzed with distilled water (18 h, 4°C, snake skin dialysis tubing 10 kDa nominal molecular weight cut-off, Fisher Scientific). The samples were freeze-dried (FreeZone 18L, Labconco, Kansas City, MO, USA) and stored at -20°C until further analysis. The protein content of the -La isolate was determined with the bicinchoninic acid (BCA) method using a Micro BCA TM Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). The -La content of the isolate was determined by reverse-phase high-performance liquid chromatography (RP-HPLC) as described by Nongonierma and FitzGerald 11 , using an -La standard sample (Sigma-Aldrich). The extraction yield and the purity of the -La obtained were calculated as described elsewhere 12 .
Enzymatic hydrolysis of the -La isolate and in vitro simulated gastrointestinal digestion (SGID) of the hydrolyzates
The outcome of the in silico analysis indicated that incubation of -La with elastase should release the greatest number of DPP-IV inhibitory peptides (Table 1) . Therefore, digestion of -La with elastase was carried out following a proof of concept experimental design approach (yielding hydrolyzates H1-H9).
The parameters of the experimental design used for -La hydrolysis with elastase consisted of the pH, temperature and E:S studied at two levels (Supplementary Table S1 ). These parameters were specifically chosen as they are key determinants of peptide release during enzymatic digestion. The pH (7.0-8.5) and temperature (37-50C) range were selected based on the optimum values for elastase as indicated by the supplier. The E:S ratio (1-2% (w/w)) was chosen based on levels which have previously been reported for the hydrolysis of whey proteins with pancreatic enzymes 13 . Each hydrolyzate was generated once with the exception of the central point condition (H5, pH 7.8 (0), 44C (0) and E:S 1.5% (0)) which was generated as two independent duplicates (H5(1) and H5 (2)). The -La isolate was resuspended (50 g L -1 on a protein basis)
in distilled water and was incubated for 30 min in a water bath at the desired temperature and pH as per the experimental design conditions. Elastase was then added to the -La suspension at the desired E:S and hydrolysis was carried out for 4 h. The pH was maintained constant by adding 0.1 M NaOH with a pH stat (Titrando 843, Tiamo 1.4 Metrohm, Dublin, Ireland). The enzyme was then heat inactivated at 90°C for 20 min. A control sample of unhydrolyzed -La underwent the same conditions as the hydrolyzate with the exception that it did not contain enzyme. H9 was subsequently subjected to in vitro SGID as described by Walsh et al. 14 . Briefly, the hydrolyzate was incubated at 37C with pepsin (E:S 1%, pH 2.0) for 90 min followed by incubation with Corolase PP (E:S 2.5%, pH 7.5) for another 150 min. The pH was maintained constant during the SGID steps using a pH stat (Metrohm). All hydrolyzates were freeze-dried post heat-inactivation and stored at -20°C prior to further analysis.
DPP-IV inhibition assay
The protein hydrolyzates were dispersed in HPLC grade water at 3.1 mg mL -1 (final concentration). The DPP-IV inhibition assay was carried out in triplicate as described by Nongonierma and FitzGerald
15
. Briefly, 25 μL sample were pipetted onto a 96 well microplate (Sarstedt, Dublin, Ireland) containing Gly-Pro-pNA (final concentration 0.200 mM). The negative control contained 100 mM Tris-HCl buffer pH 8.0 (25 μL) and Gly-Pro-pNA. The reaction was started by the addition of DPP-IV (final concentration 0.0025 U mL -1 ). The positive control was diprotin A. The microplate was incubated at 37C for 60 min in a microplate reader (Biotek Synergy HT, Winoosky, VT, USA), and the absorbance of the released pNA was monitored at 405 nm. **A disulphide bridge is present between cysteine (C) residues within the peptide.
***The DPP-IV inhibition reported by Lan, et al. 9 were < 35% when the peptides were tested at 100 µM.
For the hydrolyzates displaying DPP-IV inhibition > 50 % at 3.1 mg mL -1 , the DPP-IV IC 50 values were determined by plotting the dose-response curve (at concentrations ranging from 3.1 × 10 -2 to 3.1 mg mL -1 ). Each analysis was conducted in triplicate (n = 3).
Determination of the degree of hydrolysis (DH)
The DH was determined following the method of Adler-Nissen 17 , essentially as described in Nongonierma and FitzGerald 13 . Each experiment was carried out in triplicate (n = 3).
Gel permeation high performance liquid chromatography (GP-HPLC) and reverse-phase ultraperformance liquid chromatography (RP-UPLC) of the hydrolyzates
The -La hydrolyzates were analyzed by GP-HPLC as described in Spellman, et al. 18 . The peptide profile of the -La hydrolyzates was determined by RP-UPLC as described in Nongonierma and FitzGerald 13 .
LC-MS/MS of the -La hydrolyzates
Samples were analyzed by LC-MS/MS using an Acquity UPLC (Waters, Milford, MA, USA) coupled to a quadrupole time-offlight mass spectrometer (Q-TOF, Impact HD™, Bruker
Please do not adjust margins
Please do not adjust margins Daltonics GmbH, Bremen, Germany). The MS was fitted with an electrospray ionization (ESI) source used in positive ion mode. Hystar software (Bruker Daltonics) was used to control the instruments and to acquire data. Chromatographic separation was carried out on an Acquity BEH amide column (Waters) as described by Le Maux, et al. 19 . Fifty micrograms of
, injection volume: 10 µL) were injected onto the column. MS measurements were performed over a 70-2500 m/z acquisition range. MS data were processed on Compass DataAnalysis 4.0 SP5 (Bruker Daltonics). Peptide sequences predicted to be present by in silico model were searched for within hydrolyzate samples using the strategy described by Le Maux, et al. 19 . A mass tolerance of 0.1 Da and a time difference between the observed and predicted retention times was set at a maximum of 16 min. Peptide peak intensities in H9 and its SGID sample were visualized on Venn diagrams. MS data was analyzed using ProfileAnalysis (Bruker Daltonics) and Matlab. More than 500 compounds were detected in each sample but only peaks with an intensity > 5 × 10 5 were analyzed. The peptides observed within each sample were classified as follows: when peptide peaks had similar intensities in both samples, they were reported at the intersection of the Venn diagram and when peptide peaks within a sample had different intensities compared to the other sample (> 3 fold difference), they were reported outside of the intersection of the Venn diagram.
Statistical analysis
ANOVA was used to assess the effect of the parameters (pH, temperature and E:S) of the experimental design on DPP-IV inhibition when evaluated at 3.1 mg mL -1 at a significance level p < 0.05. The effects of the experimental design parameters on DPP-IV inhibition were tested (p < 0.05) using a multi-linear regression (MLR) model (complete model, eqn 1) as follows:
With Y, the DPP-IV inhibition of the -La hydrolyzates at 3.1 mg mL -1
; β 0 to β 3 : the coefficients of the model; pH, T (temperature) and ES (E:S): the z-centered parameters of the experimental design and ε: the residual of the model.
The model was further optimized (simplified model) by only taking into account the parameters which were significant (p < 0.1) as described by van der Ven, et al. 20 . A response surface methodology (RSM) curve was plotted using the simplified model with Matlab. The statistical treatment for DH was carried out with a one way ANOVA followed by a Student Newman-Keuls test used for multiple means comparison (p < 0.05). Statistical analyses were carried out with SPSS (version 22, SPSS Inc., Chicago, IL, USA).
Results
In silico digestion of -La
Hydrolysis of -La by five different enzyme activities (pepsin, trypsin, chymotrypsin, elastase and glutamyl endopeptidase) showed that elastase allowed the release of the highest number of previously identified DPP-IV inhibitory peptides (Supplementary Table S2 and Table 1 ). Previous studies have suggested that specific amino acids within peptide sequences correlated with DPP-IV inhibition. For instance W at position 1 and P/A at position 2 are frequently found in DPP-IV inhibitory peptides with IC 50 values < 200 µM 7, 8 . The in silico analysis did not show any peptides with a P at position 2 while two peptides with an A at position 2 were predicted to be released by following in silico digestion of -La with chymotrypsin low (KAL, (f 108-110)) and high (LAHKALCSEKLDQW, (f 105-118)) specificity. In addition, three peptides with a N-terminal W were identified following in silico digestion of -La with glutamyl endopeptidase (WVCTTFHTSGYDTQAIVQNNDSTE, (f 26-49)), pepsin (WCKDDQNPHSSNICNISCDK, (f 60-79)) and elastase (WL, (f 118-119)).
Five previously identified DPP-IV inhibitory dipeptides (GY, GL, GI, NY and WL) were predicted to be released following in silico digestion of -La by elastase (Table 1) . Of the peptides predicted to be released by elastase, WL is a relatively potent DPP-IV inhibitory peptide with an IC 50 of 43.6 µM 16 . Overall, of the enzymes studied, elastase was predicted to release the highest number of previously identified DPP-IV inhibitory peptides or peptides with DPP-IV inhibitory motifs (with a W at the N-terminus). Therefore, -La was digested with elastase to verify if these in silico predictions translated in vitro. DPP-IV inhibitory activity of the -La hydrolyzates generated within the experimental design conditions As already outlined, -La was isolated from WPC80. The RP-UPLC profile of the starting WPC80 and the -La isolate are displayed in Supplementary Fig. S1 . The isolate enriched in -La had a purity and yield of 79.3 ± 0.2 and 40.3 ± 1.4% (w/w), respectively. The generation of the hydrolyzates was reproducible as indicated by the lack of significant differences (p > 0.05) between the two independent duplicates H5(1) and H5(2) in terms of their DH, DPP-IV inhibition at 3.1 mg mL -1 and their DPP-IV IC 50 values ( Table 2) . The hydrolyzates generated at 37C (H1-H4) yielded DPP-IV inhibition < 50 % at the highest concentration tested (3.1 mg mL -1 ), resulting in it not being possible to compare all hydrolyzates based on their DPP-IV IC 50 value. Therefore, hydrolyzates were compared using the % DPP-IV inhibition observed at 3.1 mg mL -1 . The DPP-IV inhibition (at 3.1 mg mL -1 ) of the hydrolyzates varied between 23.0  6.7 and 75.8  3.7% for H3 and H9, respectively (Table 2 ). H9 had the lowest IC 50 value (1.20  0.12 mg mL -1 ).
Modelling and RSM of the DPP-IV inhibitory properties of the -La hydrolyzates generated within the experimental design conditions
A good correlation was obtained between the DPP-IV inhibition observed at 3.1 mg mL -1 and the parameters of the experimental design in the complete model (R 2 = 0.897, p = 0.00664). Temperature and E:S significantly (p < 0.05) effected DPP-IV inhibition (Table 3) .
Given the apparent lack of a pH effect on DPP-IV inhibition, the simplified model was further optimized only taking into account temperature and E:S yielding an R 2 = 0.896 (p = 0.0011). Hydrolysis temperature was found to have the greatest impact on DPP-IV inhibition as indicated by the higher coefficient associated with this parameter in the simplified model ( Table 3 ). The RSM curve generated with the simplified model illustrates the positive effect of both temperature and E:S on DPP-IV inhibition ( Supplementary Fig. S2 ). Using this proof of concept experimental design, as expected, it was predicted with the models (Table 3 ) that highest DPP-IV inhibition would be obtained at the highest levels of pH, temperature and E:S ratio employed herein, i.e., pH 8.5, 50C and an E:S of 2% (w/w). These conditions corresponded to H9 (pH 8.5, 50C and E:S of 2% (w/w)). Table 3 Multilinear regression (MLR) describing the dipeptidyl peptidase IV (DPP-IV) inhibition observed with -lactalbumin (-La) hydrolyzates evaluated at 3.1 mg mL -1 , as a function of all parameters of the experimental design (complete model) and the most significant parameters (p < 0.01, simplified model).
Parameters
Coefficient 
Physicochemical characteristics of the -La hydrolyzates
The DH of the hydrolyzates (Table 2 ) varied between 10.5  0.3 (H8) and 18.9  2.4% (H9). Differences in the peptide profile ( Supplementary Fig. S2 ) and molecular mass distribution (Fig.  1 ) of the hydrolyzates were seen. The molecular mass distribution profile showed significant protein breakdown in all hydrolyzates. Peptides were broken down to a higher extent in hydrolyzates generated at temperatures > 44C (H5-H9), with > 75% of the hydrolyzates having a molecular mass < 1 kDa. In the hydrolyzates generated at 37C (H1-H4), < 70% of the components had a molecular mass < 1 kDa (Fig. 1) .
DPP-IV inhibitory activity and physicochemical characteristics of the SGID sample of H9
Since H9 displayed the highest in vitro DPP-IV inhibition (Table  2) , this hydrolyzate was subjected to SGID. The DPP-IV IC 50 value for the SGID of H9 was 1.53  0.11 mg mL -1 . There was no significant difference (p > 0.05) between the IC 50 value of H9 before and after SGID. Differences were seen in the peptide profile of H9 following SGID, generally resulting in the presence of more intense hydrophilic peptide peaks ( Fig. 2A) . A higher proportion of peptides < 1 kDa after SGID of H9 was seen (Fig. 2 B) .
Peptide detection within H9 and its SGID sample
More than 500 compounds were detected in either H9 or its SGID sample. The peptides identified within H9 and its SGID sample ranged from 2 to 22 amino acids in length. Of the 28 peptides predicted to be released in silico following complete digestion of -La by elastase, 18 were detected by LC-MS/MS within H9 (Table 1) . As already indicated, the most abundant peptides, on the basis of their peak intensities, detected within H9 and its SGID sample were compared using a Venn diagram approach (Fig. 2C) . Sixty four high intensity peaks were common between both samples, while 82 and 86 unique peptides were detected for H9 and its SGID, respectively. In addition, several of the peptides detected within H9 and its SGID samples, displayed the features of known-DPP-IV inhibitory peptides consisting of W at the N-terminus, P/A at position 2 or P at the C-terminus (Supplementary Table S3 ).
Discussion
-La has been shown to possess several relatively potent DPP-IV inhibitory peptides within its sequence 7 . Therefore, the development of enzymatic strategies for the targeted release of such peptides is of interest. The role of W-containing peptides in in vitro DPP-IV inhibition has been demonstrated 21 . Interestingly, -La is the bovine milk protein with the highest W content. In silico digestion of -La was applied in order to predict the release of peptides which were then compared to known DPP-IV inhibitory peptides. Elastase has been shown to cleave at the C-terminal side of L, A, V and I 22 .
Experimental designs have previously been applied to optimize the release of milk protein-derived bioactive peptides, particularly for the generation of angiotensin converting enzyme (ACE) inhibitory and antioxidant peptides 20, [23] [24] [25] . To our knowledge, this approach has not been previously used in combination with in silico analysis to optimize the hydrolysis of food proteins for the generation of DPP-IV inhibitory peptides. It was found in this proof of concept study that temperature and E:S had a significant (p < 0.05, simplified model) effect on the release of DPP-IV inhibitory peptides, with the temperature having the highest effect (Table 3) . This result is similar to an earlier study also showing that hydrolysis temperature played a greater role than the E:S in the release of antioxidant peptides upon hydrolysis of whey proteins with thermolysin 23 . In contrast, Naik, et al. 25 reported that pH and E:S had an effect on the release of antioxidant peptides from whey proteins hydrolysed with trypsin, while temperature did not. While no significant (p > 0.05) effect of hydrolysis pH on DPP-IV inhibition was seen herein, some differences were visible in terms of the physicochemical characteristics of the hydrolyzates generated at different pHs ( Fig. 1 and Supplementary Fig. S3 ). For example, for hydrolyzates generated at 50C and an E:S of 2%, differences in peptide peak intensities were seen between H7 (pH 7.0) and H9 (pH 8.5), particularly at retention times of 0.6 and 7.7 min. Of the 28 predicted sequences, including disulfide linked peptides, only 18 peptides were detected in H9 (Table 1) . This may arise from the fact that -La possesses secondary/tertiary structure, making it challenging to predict peptide release using peptide cutter programs which rely solely on the primary sequence of the protein. Furthermore, in silico digestion does not account for partial proteolysis. While combinations of in silico and in vitro approaches may be beneficial to develop bioactive dietary protein hydrolysates, some limitations exist. Cleavage specificity of enzymes generally only considers major cleavage sites. However, some secondary cleavage sites may exist, which are generally not taken into account in peptide cutter programmes. In addition, side activities may be found within enzyme preparations, which further yield to the release of peptide sequences which were not predicted to be released when using in silico digestion methods. Furthermore, protein/peptide digestion is highly dependent on the conditions employed during enzymatic hydrolysis (i.e., temperature, time, pH, E:S ratio, etc.). 20 For all the above reasons, it is quite challenging to directly translate in silico predictions to actual in vitro peptide release.
Numerous peptides identified within H9 were also detected in its SGID sample ( Table 1) . Five of these peptides (GY, GL, GI, NY and WL) were previously identified as DPP-IV inhibitors. Similarly, WV (f 24-25), a potent DPP-IV inhibitory peptide (IC 50 = 65.7 µM 15 ) was also identified by LC-MS/MS within the two samples (data not shown). In addition, several peptides within these two samples displayed the features of previously identified DPP-IV inhibitory peptides. However, these additional peptides may have only been present at low concentrations as none of these appear to originate from -La (Supplementary Table S3 ). Therefore, it is expected that their contribution to the overall DPP-IV inhibition is minor. Thus, the peptides GY, GL, GI, NY, WL and WV may, in part, be responsible for the DPP-IV inhibitory properties of the hydrolyzates. Quantification of these peptides within the hydrolyzate samples may help to better understand their overall contribution to the DPP-IV inhibition observed and also to determine their extent of release from -La following enzymatic digestion. However, peptide quantification was not embarked upon during the present study.
To date, two studies have shown that ingestion of DPP-IV inhibitory milk protein hydrolyzates in vivo could reduce serum glucose level in small animals 26, 27 . A direct link with in vivo DPP-IV inhibition had not been established in these studies. While other animal trials carried out with zein 28 , rice , p > 0.05, for H9 and its SGID sample, respectively). However, the RP-UPLC and molecular mass distribution profiles of H9 and its SGID sample differed ( Fig. 2A  and 2B) . Furthermore, major differences in terms of peptide peak intensities were observed before and after SGID (Fig. 2C) . This indicates that the peptides within H9 were significantly degraded during incubation with the gastrointestinal enzymes.
Conclusion
In silico analyses based on a peptide cutter approach allowed the design of a proof of concept experimental procedure to specifically release previously identified DPP-IV inhibitory peptides from -La. Hydrolysis with elastase was predicted to release five previously identified DPP-IV inhibitory peptides (i.e., GY, GL, GI, NY and WL). During in vitro enzymatic digestion of -La with elastase, temperature had the highest effect (p < 0.05) on the release of DPP-IV inhibitory peptides followed by the E:S (p < 0.05). Several previously identified DPP-IV inhibitory peptides were observed by LC-MS/MS in the most potent DPP-IV inhibitory -La hydrolyzate, H9. Following SGID, major differences were seen in the peptides within H9. However, potent DPP-IV inhibitory activity was also found within the SGID sample, showing promise in terms of the potential oral application of H9 as an ingredient for serum glucose lowering properties in humans. In vivo assessment of the hydrolyzates is required to evaluate their potential role as DPP-IV inhibitors in humans.
Please do not adjust margins Please do not adjust margins Supplementary Table S2 . Results of the in silico digestion of -lactalbumin (-La) with pepsin, trypsin, chymotrypsin and glutamyl endopeptidase. 
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Please do not adjust margins Please do not adjust margins Supplementary Table S3 . Peptide sequences identified by LC-MS within the -lactalbumin (-La) H9 and its associated simulated gastrointestinal digest (SGID) sample, which present structural features of known dipeptidyl peptidase IV inhibitory peptides (i.e., W at the N-terminus, P/A at position 2 or P at the C-terminus 7, 8, 33 ). These peptides have not previously been evaluated for their DPP-IV inhibitory potential, therefore, their DPP-IV inhibitory properties are not known. 
